SMS PharmaceuticalsQ2 FY24

SMS Pharmaceuticals Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹486.5P/E: 39.0Market Cap: ₹4.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

No

0 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • SMS Pharmaceuticals anticipates maintaining steady growth with a 10-15% year-on-year increase in revenues.
  • The company expects to achieve all-time high sales in the next 2-3 financial years if current trends continue.
  • Growth drivers include key segments like ARV, Ibuprofen, anti-diabetic, anti-ulcer, anti-migraine, and anti-inflammatory APIs.
  • Ibuprofen volumes have shown consistent month-on-month growth; capacity utilization is targeted to increase to about 75% by FY25.
  • The ARV segment, after some delays, is expected to sustain steady sales with good demand visibility beyond March.
  • The company is also exploring new product launches and niche segments with higher realizations.
  • Backward integration and cost optimization measures are expected to enhance margins and support growth.
  • Expansion into contract development and manufacturing opportunities is under consideration but not yet finalized.

See what SMS Pharmaceuticals management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • There is no mention of any major capital expenditure (capex) expansion or new fundraising through debt or equity currently planned.
  • The company is focusing on consolidating its recent major expansion, especially in Ibuprofen capacity, before considering further capacity increases.
  • Regular small capex expansions are ongoing, but no significant fundraising activities have been indicated.
  • The management emphasizes consolidation and organic growth rather than immediate fundraising.
  • Future plans may include product and capacity expansions but no specifics about debt or equity raising were provided in the call.

See what SMS Pharmaceuticals management said on order book — free account, 30 seconds.

Capex plans

No
  • No major capex expansions are planned in the near term.
  • The company has recently completed a significant expansion of Ibuprofen capacity.
  • Current focus is on consolidating operations post the recent capacity expansion.
  • Small, regular capex investments will continue as part of routine operations.
  • Future capacity utilization target is around 75% by FY25, which may guide subsequent expansion decisions.
  • Product lineup expansion is ongoing with a good pipeline of products approaching commercialization.
  • The company is exploring contract development and manufacturing (CDMO) opportunities selectively but no finalized investments yet.

Track SMS Pharmaceuticals — get its next earnings analysis in your feed

How does SMS Pharmaceuticals rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSMS Pharmaceuticals
Rev 3Mar 3

How does SMS Pharmaceuticals rank in Pharmaceuticals & Biotechnology?

Compare SMS Pharmaceuticals against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →